Orion constellation glows red in gorgeous deep space photo
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Miguel Claro is a professional photographer, author and science communicator based in Lisbon, Portugal, who creates spectacular images of the night sky. As a European Southern Observatory Photo Ambassador and member of The World At Night and the official astrophotographer of the Dark Sky Alqueva Reserve, he specializes in astronomical "Skyscapes" that connect both Earth and the night sky.
This deep view of the Orion Constellation glows in reddish hues thanks to a filtered view of hydrogen alpha emission, a type of light emitted by hydrogen atoms.
The large, intricate semi-circle around the three stars that make up Orion's belt is known as Barnard's Loop (Sh2-276), a nebula about 1,600 light-years away that itself spans some 300 light-years across. Barnard's Loop is part of the even bigger Orion molecular cloud complex, made up of dust, hydrogen and helium, and is the birthplace of stars.
I always wanted to make an image like this one that shows all the beautiful reddish hydrogen that surrounds one of the most spectacular and colorful regions of the entire night sky as seen from Earth. This cloud contains known wonders like M42, Horse Head, LDN 1622, the large Lambda Orionis Ring and the bluish (OIII) Witch Head Nebula, close to Rigel star.
I had my set up for this shot (Samyang 35mm f1.8 with Poseidon C Pro) available and prepared for two months before Orion cooperated. This image was a bit challenging to capture, due to uncooperative weather and the fact that the Orion constellation was beginning to set early along the western horizon.
I only had 40 minutes available for each clear night between February and March 2025 as seen from the Dark Sky Alqueva Reserve in Portugal, so collecting the seven hours of data in total for this image took many nights. Had I taken it in the beginning of winter, I could have taken it in one night. I hope you enjoy the result.
I hope you enjoy it as much as I do, and if you want to support my work as an independent artist, you can buy one of my images as a print and a piece of art or a wall decor for your sweet home! Explore the size options and different types available on my Print gallery. Meanwhile, you can sign-up my newsletter to get early access of future releases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Some people are turning to nicotine gum and patches to treat long COVID brain fog
Some people with long COVID are turning to an unlikely remedy: nicotine gum and patches. Though typically used to quit smoking, nicotine is now being explored as a possible way to ease symptoms such as brain fog and fatigue. One such case, detailed in a recent article in Slate, describes a woman who found significant relief from debilitating brain fog after trying low-dose nicotine gum. Her experience, while anecdotal, aligns with findings from a small but interesting study from Germany. The study involved four participants suffering from symptoms related to long COVID. The researcher administered low-dose nicotine patches once daily and noticed marked improvements in the participants' symptoms. Tiredness, weakness, shortness of breath and trouble with exercise rapidly improved – by day six at the latest. For those who had lost their sense of taste or smell, it took longer, but these senses came back fully within 16 days. Although it's not possible to draw definitive conclusions on cause and effect from such a small study, the results could pave the way for larger studies. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. While some people slowly recover from COVID, others remain unwell for years, especially those who became sick before vaccines were available. Between 3% and 5% of people continue to experience symptoms months, and sometimes even years, after the initial infection. In the UK, long COVID affects around 2.8% of the population. Brain fog and other neurological symptoms of long COVID are thought to result from a combination of factors – including inflammation, reduced oxygen to the brain, vascular damage and disruption to the blood-brain barrier. Research continues as there is still a lot we don't know about this condition. The researcher in the German study thinks that long COVID symptoms, such as fatigue, brain fog and mood changes, might partly be due to problems with a brain chemical called acetylcholine, a neurotransmitter. This chemical is important for many functions in the body, including memory, attention and regulating mood. Normally, acetylcholine works by attaching to special 'docking sites' on cells called nicotinic acetylcholine receptors, which help send signals in the brain and nervous system. But the COVID virus may interfere with these receptors, either by blocking them or disrupting how they work. When this happens, the brain may not be able to send signals properly, which could contribute to the mental and physical symptoms seen in long COVID. So why would nicotine potentially be useful? Nicotine binds to the same receptors and might help restore normal signalling, but the idea that it displaces the virus directly is still speculative. Nicotine is available in different forms, such as patches, gum, lozenges and sprays. Using nicotine through the skin, for example, with a patch, keeps the amount in the blood steady without big spikes. Because of this, people in the study didn't seem to develop a dependence on it. Chewing nicotine gum or using a lozenge can cause spikes in nicotine levels, since the nicotine is absorbed gradually through the lining of the mouth. But unlike a patch, which delivers a steady dose, the user has more control over how much nicotine they take in when using gum or lozenges. There are mixed results on the effectiveness of nicotine on cognitive functions such as memory and concentration. But most studies agree that it can enhance attention. Larger studies are needed to gauge the effectiveness of nicotine specifically for long COVID symptoms. Despite its benefits, nicotine is not without risks. Even in gum or patch form, it can cause side-effects like nausea, dizziness, increased heart rate and higher blood pressure. Some of these stimulant effects on heart rate may be useful for people with long COVID symptoms such as exercise intolerance. But this needs to be closely monitored. Long-term use may also affect heart health. For non-smokers, the risk of developing a nicotine dependency is a serious concern. So are there any options to treat long COVID symptoms? There are some studies looking at guanfacine in combination with N-acetylcysteine, which have shown improvement in brain fog in small groups of people. There has been at least one clinical trial exploring nicotine for mild cognitive impairment in older adults, though not in the context of long COVID. Given that anecdotal reports and small studies continue to draw attention, it is likely that targeted trials are in development. The main recommendations by experts are to implement lifestyle measures. Slowly increasing exercise, having a healthy diet, avoiding alcohol, drugs and smoking, sleeping enough, practising mindfulness and doing things that stimulate the brain are all thought to help brain fog. For those grappling with long COVID or persistent brain fog, the idea of using nicotine patches or gum might be tempting. But experts caution against self-medicating with nicotine. The lack of standardised dosing and the potential for addiction and unknown long-term effects make it a risky experiment. While nicotine isn't a cure and may carry real risks, its potential to ease long COVID symptoms warrants careful study. For now, those battling brain fog should approach it with caution – and always under medical supervision. What's clear, though, is the urgent need for more research into safe, effective treatments for the lingering effects of COVID. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Yahoo
2 hours ago
- Yahoo
New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — "adipose-derived stem cells (ASCs)" — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss. The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP). Hairstylists And Medical Expert Confirm Temporary Hair Loss Affecting Ozempic Users Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth. The researchers concluded that hair regrowth was improved in "all experimental groups" where male mice received stem cell solutions supplemented with ATP. Read On The Fox News App The findings were published in the journal Stem Cell Research & Therapy. Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital. This Daily Beauty Routine Could Be Ruining Your Hair, Experts Warn "We expected good results, but not such a high level of success," he said. "We're talking about a very high degree of hair regrowth in both male and female mice." With appropriate doses, the researchers achieved "very high percentages" of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. "These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available," Bran went on. "Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone." The main limitation of the study was the thinness of mouse skin, Bran noted, which "posed a challenge in administering the therapy." "This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin," he said. These new findings should be "interpreted with caution and scientific rigor," Bran cautioned. "Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed." Click Here To Sign Up For Our Health Newsletter The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops. "It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits," Bran added. Looking ahead to human clinical trials, researchers are "actively working" on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted. "If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years," he said. In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method. "While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia," he reiterated. For more Health articles, visit "This study is small, and more research is needed on this method as a potential treatment option for androgenetic alopecia." Until then, Camp encourages people to focus on currently available and "well-studied" treatments to address hair loss, and to visit a board-certified dermatologist for article source: New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
Yahoo
2 hours ago
- Yahoo
Protein Breakthrough Could Extend Healthy Lifespan, Study Finds
A protein called Klotho, when boosted, helps mice live longer and age healthier, offering a potential new path for anti-aging treatments in humans, according to a groundbreaking study from the Universitat Autònoma de Barcelona (UAB). Published in Molecular Therapy and led by Professor Miguel Chillón, the study found that a specific form of Klotho, known as secreted Klotho (s-KL), improved muscle strength, bone health, and brain function in treated mice. These mice lived 15–20% longer than untreated peers, reaching the human equivalent of about 70 years with greater physical and mental vitality. Klotho is known to combat inflammation and oxidative stress, key drivers of aging. Unlike other forms of the protein, s-KL circulates freely in the body without disrupting systems like calcium metabolism, making it a safer candidate for therapies. 'If we can find a viable delivery method, s-KL could make a significant contribution to improving people's quality of life,' the researchers said, per The Brighter Side of News. 'It could help build the healthiest society possible.' Using gene therapy with adeno-associated viruses (AAV9), scientists delivered s-KL through the bloodstream and directly into the brain, targeting areas critical for muscle and memory. Three groups of mice were treated: one at six months (young adulthood), another at 12 months (middle age), and a control group. By 24 months, treated mice showed stronger muscles with larger fibers, less fibrosis, and enhanced repair by satellite cells. Bone structure, particularly in females, remained more intact, suggesting protection against osteoporosis. 'KL treatment improved physical fitness, related to a reduction in muscle fibrosis and an increase in muscular regenerative capacity,' the researchers noted, The Brighter Side reported. In the brain, s-KL promoted new neuron growth in the hippocampus, the memory center, and boosted immune processes like phagocytosis, where cells clear toxic waste. This cleanup is vital as aging glial cells often fail to remove debris, contributing to cognitive decline. Transcriptomic analysis revealed increased gene activity tied to immune response and brain cell regeneration. 'We now have viral vectors that can reach the brain after being administered intravenously, which would make it easier to safely transfer this therapy to humans,' said Joan Roig-Soriano, the study's first author, per The Brighter Side. The findings aim to extend health span — the years spent in good health — rather than just lifespan. The team has filed patents for using Klotho to support cognition, strengthen bones and muscles, and increase longevity. While gene therapy was used in the study, direct protein delivery as a drug is also being explored, though a reliable method to target tissues without side effects is still needed. With global populations aging — experts predict a quarter of people in developed countries will be over 65 by 2060 — such treatments could ease the burden on health systems by preventing age-related diseases before they start. The study's results suggest Klotho could redefine aging, offering a future where decline is not inevitable.
